Attorney General Raúl Torrez Secures Insulin Affordability Agreements with Sanofi and Novo Nordisk

Courtesy of NM Deptartment of Justice

Albuquerque, NM – Attorney General Raúl Torrez announced settlements with two major insulin manufacturers—Sanofi-Aventis U.S. LLC and Novo Nordisk Inc.—that will dramatically reduce the cost of insulin for tens of thousands of New Mexicans. The agreements represent a major step toward ensuring affordable, equitable access to life-saving medication for individuals managing diabetes.

“These are huge wins for New Mexicans who have struggled with the outrageous cost of insulin,” said Attorney General Raúl Torrez. “These agreements will help people stop rationing medication, avoid financial hardship, and focus on staying healthy. We are holding drug manufacturers accountable and making access to life-saving treatment more equitable.”

Approximately 207,000 to 250,000 New Mexicans live with diabetes, a condition that often requires daily insulin. High out-of-pocket costs have historically forced many patients to make difficult choices between purchasing insulin and meeting basic needs.

Settlement with Sanofi:

• $35 Monthly Cap: Sanofi must maintain its Insulins ValYou Savings Program, ensuring eligible cash-paying patients can access a 30-day insulin supply for $35.
• Free Insulin for Low-Income Patients: Sanofi will continue its Patient Connection Program for uninsured or underinsured individuals.
• Bilingual Support and More: Live phone and translation support in Spanish, Hmong, Somali, and Mandarin Chinese.
• Pharmacy Outreach: Participating pharmacies will receive training to help patients enroll in affordability programs.

Settlement with Novo Nordisk:

• $35 Monthly Cap: Novo Nordisk will ensure that eligible New Mexicans can access a monthly insulin supply for no more than $35.
• Free Insulin for Low-Income Patients: Novo Nordisk will maintain its Patient Assistance Program, offering free insulin to qualifying uninsured or Medicare Part D enrollees.
• Real-Time Pharmacy Messaging: Novo Nordisk will partner with third-party messaging services to notify pharmacies about available discounts at the point of sale and help patients enroll on the spot.
• Bilingual Customer Service: Live phone and website chat support available in Spanish.

“These agreements are a major milestone in our broader effort to bring transparency and fairness to the pharmaceutical industry,” said Torrez. “Our office will continue working to ensure every New Mexican has access to essential medicine—regardless of income or insurance status.”
Both settlements follow independent investigations by the New Mexico Department of Justice into insulin pricing practices. Both companies have committed to sweeping reforms that will make insulin more affordable and accessible across the state for several years.

For more information on the affordability programs and eligibility, visit www.novocare.com for Novo Nordisk programs and Sanofi’s Patient Connection Program for Sanofi resources.

Copies of both agreements are below:

New Mexico – Sanofi Settlement Agreement
​
NNI – NM Settlement Agreement 5-20-2025